Global influenza therapeutics market is anticipated to grow significantly during forecast period due to growing prevalence of influenza, increasing demand for treatment medication, government initiatives in awareness and treatment would drive the growth of influenza therapeutics market globally.

The report titled “Influenza Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall influenza therapeutics market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on technology and different geographical regions.

Geographically, the global influenza therapeutics market is studied for the following regional markets:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global influenza therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global influenza therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global Influenza therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.      

Thus, the research study provides a holistic view of the global influenza therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on therapy type, the global influenza therapeutics market is segmented as follows:  

• Vaccines
  • Trivalent
  • Quadrivalent
• Drugs
  • Zanamivir
  • Oseltamivir
  • Peramivir
  • Other

Influenza is an acute respiratory disease caused by influenza type A, B or C viruses infection, preventable by vaccination or chemoprophylaxis and is treatable by specific antiviral drugs. The  World Health Organization (WHO) reports that throughout the world, annual outbreaks result in 3–5 million severe cases and between 250,000- 500,000 deaths. Currently, influenza vaccines (also known as flu shots or jabs) dominating the global influenza market because government initiative for vaccination is prime factor that driving the growth of influenza vaccine market globally; The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), European Centre for Disease Prevention and Control recommends yearly vaccination for nearly all people over the age of six months, especially those at high risk. CDC recommended oral oseltamivir (Tamiflu), inhaled zanamivir (Relenza), and intravenous peramivir (Rapivab) antiviral medications for the treatment; and trivalent- quadrivalent vaccines for the prevention of influenza, these all factors assisting growth of influenza market globally. 

For the purpose of this study, the global influenza therapeutics market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

The World Health Organization (WHO) reports that throughout the world, annual outbreaks result in 3–5 million severe cases and between 250,000 and 500,000 deaths occurs due to influenza infection. It is observed that, currently North America followed by Europe dominating the global influenza market because government initiative such as Centers for Disease Control and Prevention (CDC), The European Centre for Disease Prevention and Control recommends yearly influenza vaccination for nearly all people over the age of six months, especially those at high risk are primarily driving the growth of influenza market in these region. Also some factors such as growing incidence of infectious diseases, higher healthcare awareness and increase in aging population are fueling the market growth in developed regions. On the other hand, Asia Pacific expected to grow at the highest CAGR during forecast period due to the higher number of targeted population, rising healthcare awareness and government initiatives in prevention of infectious disease would assist the market growth during forecast period in Asia Pacific region.